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Resolution of acute inflammation is an active process
that involves the biosynthesis of specialized prore-
solving lipid mediators. Among them, resolvin D1
(RvD1) actions are mediated by two G protein–cou-
pled receptors (GPCRs), ALX/FPR2 and GPR32, that
also regulate specific microRNAs (miRNAs) and their
target genes in novel resolution circuits. We report
the ligand selectivity of RvD1 activation of ALX/FPR2
and GPR32. In addition to RvD1, its aspirin-triggered
epimer and RvD1 analogs each dose dependently and
effectively activated ALX/FPR2 and GPR32 in GPCR-
overexpressing -arrestin systems using lumines-
cence and electric cell–substrate impedance sensing.
To corroborate these findings in vivo, neutrophil in-
filtration in self-limited peritonitis was reduced in
human ALX/FPR2-overexpressing transgenic mice
that was further limited to 50% by RvD1 treatment
with as little as 10 ng of RvD1 per mouse. Analysis of
miRNA expression revealed that RvD1 administration
significantly up-regulated miR-208a and miR-219 in ex-
udates isolated from ALX/FPR2 transgenic mice com-
pared with littermates. Overexpression of miR-208a in
human macrophages up-regulated IL-10. In compari-
son, in ALX/FPR2 knockout mice, RvD1 neither signifi-
cantly reduced leukocyte infiltration in zymosan-in-
duced peritonitis nor regulated miR-208a and IL-10 in
these mice. Together, these results demonstrate the se-
lectivity of RvD1 interactions with receptors ALX/FPR2
and GPR32. Moreover, they establish a new molecular
circuit that is operative in the resolution of acute inflam-
mation activated by the proresolving mediator RvD1
involving specific GPCRs and miRNAs. (Am J Pathol
2012, 180:2018–2027; DOI: 10.1016/j.ajpath.2012.01.028)
2018Chemical mediators regulate acute inflammation and reso-
lution, exerting their actions via cell surface G protein–cou-
pled receptors (GPCRs).1,2,3 Results from this laboratory
demonstrated that resolution of self-limited inflammation is
an active process that involves local and temporal bio-
synthesis of a new genus of specialized proresolving lipid
mediators. Specialized proresolving lipid mediators in-
clude several structurally distinct families, including li-
poxins from arachidonic acid, resolvins of the E-series,
resolvins of the D-series, protectins, and, most recently,
maresins, which are enzymatically biosynthesized from
the -3 fatty acids eicosapentaenoic acid and docosa-
hexaenoic acid (DHA) (for a recent review, see the article
by Serhan3). Specialized proresolving lipid mediators are
bioactive chemical autacoids, carry potent and protec-
tive actions in disease models, and act on specific cel-
lular targets in a stereoselective manner.
Specialized proresolving lipid mediators exert their ac-
tions via cell surface GPCRs.3 Lipoxin A4 (LXA4) interacts
with ALX/FPR2,4–6 signals to stop further polymorphonu-
clear neutrophil (PMN) infiltration, and stimulates nonphlo-
gistic monocyte recruitment7 and macrophage phagocyto-
sis of apoptotic PMNs.8,9 In humans, the aspirin-triggered
15-epimer of LXA4 and the expression level of ALX/FPR2 in
skin blisters delineated between resolving versus delayed
resolution.10 A member of the D-series resolvins, namely,
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AJP May 2012, Vol. 180, No. 5resolvin D1 (RvD1), biosynthesized from the n-3 essential
fatty acid DHA, was first identified in resolving inflammatory
exudates from acute self-limited murine peritonitis.11 RvD1
biosynthesis and structure were elucidated,11 and its com-
plete stereochemistry was established as 7S,8R,17S-trihy-
droxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid.12
Low-dose aspirin treatment triggers epimers in lipoxins
and resolvins, initiating novel aspirin-triggered biosyn-
thetic pathways. For example, these aspirin-triggered
routes lead to the biosynthesis of 15R-LXA4
13 and 17R-
RvD111 and to the inhibition of classic cyclooxygenase
pathway products, eg, prostaglandins and thrombox-
anes.3,14 These aspirin-triggered endogenous epimers of
natural anti-inflammatory and proresolving mediators are
of particular interest because they resist the rapid local
enzymatic inactivation of these autacoids.12,15 Stable an-
alogs, including 17(R/S)-methyl RvD1, were designed to
mimic the aspirin-triggered form of RvD1 and were pre-
pared by total organic synthesis to give potent and pro-
tective actions in ischemia-reperfusion injury; RvD1 and
17(R/S)-methyl RvD1 protected lungs from PMN infiltra-
tion and second organ injury (see Kasuga et al16 and the
recent review by Serhan and Petasis17).
RvD1 and aspirin-triggered RvD1 (AT-RvD1) display sim-
ilar actions, each reducing PMN infiltration by 50% in the
murine dorsal air pouch at equal doses of 100 ng per
mouse. In murine peritonitis, RvD1 and AT-RvD1 also
proved equipotent (at nanogram dosages), limiting PMN
infiltration in a dose-dependent manner. They were as po-
tent as indomethacin, a well-characterized nonsteroidal
anti-inflammatory drug, in reducing PMN infiltration.11,12,18
In mouse kidneys, RvD1 is generated in response to bilat-
eral ischemia-reperfusion injury.19 Administration of RvDs
before or after ischemia results in a reduction in functional
and morphologic kidney injury. RvD1 also displays potent
ocular actions, reducing retinopathy20 and suture-in-
duced corneal neovascularization.21 As a potent resolu-
tion agonist, RvD1 also attenuates inflammatory pain.22
AT-RvD1 is antihyperalgesic in adjuvant-induced arthri-
tis23, and RvD1 and AT-RvD1 each block activities of
specific transient receptor potential channels, attenuat-
ing acute pain behaviors and reversing mechanical and
thermal hypersensitivity associated with inflammation.24
Recently, AT-RvD1 proved to prevent experimental coli-
tis.25 In these studies, systemic treatment with AT-RvD1
(in nanogram ranges) greatly improved disease severity,
including colonic damage, PMN infiltration, and body
weight loss in dextran-sulfate-sodium– and 2,4,6-trinitro-
benzene-sulfonic-acid–induced colitis. In obese diabetic
mice, RvD1 improves insulin sensitivity and reduces
macrophage accumulations in adipose tissues.26 Hence,
these results suggest that RvD1, AT-RvD1, and their sta-
ble analogs could provide a novel approach to stimulate
resolution, treating a range of inflammatory disorders.
Two specific human GPCRs, ALX/FPR2 and GPR32,
mediate RvD1’s proresolving actions on human phago-
cytes.27 Actions of RvD1 in vivo are mediated, in part, by
molecular circuits involving microRNAs (miRNAs) miR-
146b, miR-219, and miR-208a and their target genes,
which are regulated by these receptors.28 miRNAs are
emerging as key regulators of the immune response andinflammation-related diseases such as cancer.29 Earlier,
we identified the first miRNA signature of resolution as
part of the molecular circuit that actively drives the return
to homeostasis.28 Herein, we determined the ligand se-
lectivity of RvD1, its aspirin-triggered epimer AT-RvD1,
and their stable analogs using the recently identified cog-
nate receptors human GPR32 (hGPR32: DRV1) and hu-
man ALX/FPR2 (hALX/FPR2) and their ability to regulate
PMN infiltration and specific miRNAs in vivo.
Materials and Methods
GPCR–-Arrestin System and Ligand-Receptor
Interactions
Ligand-receptor interactions were monitored using the
-arrestin PathHunter system (DiscoveRx, Fremont,
CA)30 and were performed essentially as in the study by
Krishnamoorthy et al,27 with CHO cells stably overex-
pressing recombinant hGPR32 (CHO-hGPR32) or HEK
cells stably expressing hALX/FPR2 receptors (HEK-
hALX/FPR2) tagged with the Pro-Link label of -galacto-
sidase and -arrestin linked to the enzyme acceptor frag-
ment of -galactosidase. Briefly, specific ligand-receptor
interactions on incubation with tested compounds (1 hour
at 37°C) were determined by measuring chemilumines-
cence using the PathHunter detection kit (DiscoveRx).
RvD1 and AT-RvD1 were prepared by total organic syn-
thesis, and their physical and spectroscopic properties
were matched with biogenic products using published
criteria as reported in several studies.11,12,18 17(R/S)-
methyl RvD1 was also synthesized by total organic syn-
thesis.16 Ligand-receptor interactions were monitored us-
ing HEK-hALX/FPR2 or CHO-hGPR32. Each compound
was tested from 10-12 to 10-7 mol/L. EC50 values were
calculated using GraphPad Prism software (GraphPad
Software Inc., San Diego, CA). For methyl ester prepara-
tion, RvD1 was treated with excess ethereal diazometh-
ane, taken to dryness with nitrogen gas, suspended in
methanol, and isolated using high-performance liquid
chromatography. The physical integrity of RvD1 and
each related compound was confirmed just before the
bioassays.
Ligand Selectivity Using an ECIS System
Ligand-receptor interactions were monitored by measur-
ing impedance31 across cultured CHO-hGPR32 cell
monolayers using an electric cell–substrate impedance
sensing (ECIS) system (Applied Biophysics, Troy, NY).
Briefly, cells were plated at 0.1 106 per well of an 8-well
ECIS array (8W10E). Cells were examined 24 hours
after plating. RvD1 and related compounds were added
to the chambers in serum-free medium, and real-time
impedance changes were monitored (0 to 30 minutes,
37°C).
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Fluorescence-Activated Cell Sorter Staining
Genetically engineered mice were produced and geno-
typed as reported earlier.32,33 All the animal experiments
were performed in accordance with the Harvard Medical
School Standing Committee on Animals guidelines for
animal care (Protocol 02570). Briefly, mice were anesthe-
tized with isoflurane (Aerrane; Baxter, Deerfield, IL) and
were treated with either RvD1–methyl ester (RvD1-ME; 10
ng) or vehicle, i.v. in 100 L of sterile saline followed by
i.p. with 1 mg of zymosan A in 1 mL of sterile saline.
Twenty-four hours after injection, mice were euthanized
with an overdose of isoflurane, and peritoneal exudates
were collected to determine exudate leukocyte numbers
and flow cytometry of PMN (with anti-Ly-6G antibody;
eBioscience Inc., San Diego, CA) and monocytes/mac-
rophages (with anti-F4/80 antibody; eBioscience).
miRNA Isolation, Reverse Transcription, and
Real-Time PCR
miRNA isolation and real-time PCR were performed as in
the study by Recchiuti et al.28 Briefly, miRNA fractions from
exudate cells collected from mice or human macrophages
were isolated using an miRNA isolation kit (Roche Applied
Science, Indianapolis, IN) and were quantitated using a
spectrophotometer (NanoDrop, Thermo Fisher Scientific
Inc., Wilmington, DE) at the Biopolymers Facility at Harvard
Medical School (Boston, MA). miRNA samples were then
reverse transcribed using the miScript reverse transcription
kit (Qiagen Inc., Valencia, CA), followed by real-time PCR
with specific primers for each miRNA in a SYBR green–
based detection system. PCR was performed using an
ABI7900HT thermal cycler (Applied Biosystems, Foster
City, CA), and the results were analyzed using SDS soft-
ware version 2.4 (Applied Biosystems). miRNA expression
levels were calculated using the 2–CT relative quantita-
tion34 after normalization to housekeeping genes using
RNAU1A and small Cajal body-specific RNA 17
(SCARNA17, NCBI accession no. NR_003003) for mouse
miRNA and the small nuclear RNA U1 (RNAU1A; NCBI
accession no. NR_004421) for human macrophages.
Human Macrophages, Transfection, and IL-10
Production
Human monocytes were isolated by adherence from pe-
ripheral blood mononuclear cells27 from deidentified
healthy human volunteers from Children’s Hospital Boston
blood bank. The cells were cultured in RPMI supplemented
with recombinant granulocyte-monocyte colony-stimulating
factor (10 ng/mL) for macrophage differentiation. On day 7,
macrophages were transfected with miR-208a expression
vector or mock vector (OriGene Technologies Inc., Rock-
ville, MD) using the jetPEI macrophage transfection re-
agent (Polyplus, Ilkrich, France) with 5 g of expression
vector per 2.5  106 cells. Seventy-two hours after trans-
fection, miRNA was isolated and subjected to real-time
PCR to verify overexpression of miR-208a. Supernatantswere collected, and IL-10 levels were determined using
an enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN) and were normalized to total superna-
tant proteins measured using the Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
Statistical significance between two groups was evalu-
ated using the 2-tailed Student’s t-test. A P  0.05 was
considered significant. For determining significance
among groups in the peritonitis experiment, one-way
analysis of variance was used, and P  0.05 across the
groups was considered significant.
Results
RvD1, Its Aspirin-Triggered Epimer AT-RvD1,
and Their Stable Analogs Directly Activate
hALX/FPR2 and hGPR32
We first evaluated the activation of hGPR32 and hALX/
FPR2 by AT-RvD1, RvD1-ME, 17(R/S)-methyl RvD1-ME
and its precursor n-3 fatty acid DHA using the -arrestin–
based ligand-receptor interaction system.27 Each of the
related RvD1 products are potent bioactive analogs.12,16
At equimolar concentrations, RvD1, AT-RvD1, RvD1-ME,
and 17(R/S)-methyl RvD1-ME directly activated hALX/
FPR2 (Figure 1) and hGPR32 (Figure 2), with EC50 values
in the low picomolar range (Table 1). In comparison, the
RvD1 precursor DHA required log orders of magnitude
higher concentrations to activate the tagged -arrestin
recruitment in these cells (Figures 1 and 2). At 109
mol/L, within the bioactive range of RvD1,11,12 DHA was
far less effective (Figure 1A), displaying 10% maximal
activity of RvD1 with GPR32 and 50% maximal activity
A B
C D
Figure 1. RvD1, AT-RvD1, and their stable analogs directly act on hALX/
FPR2. Ligand-receptor interaction was monitored using the HEK-ALX/FPR2
-arrestin system (see Materials and Methods). Dose-response activation
curves were obtained for RvD1 and DHA (A), RvD1-ME (B), 17(R/S)-methyl
RvD1-ME (C), and AT-RvD1 (D). Results are expressed as mean  SEM (n 
3 to 4). RLU, relative luminescence units.with the hALX/FPR2 recombinant system.
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Receptor-Dependent Impedance Changes
To further examine ligand-receptor relationships, we
used an ECIS system, which monitors changes in imped-
ance on ligand binding to receptors.31 In this system,
RvD1 dose dependently (ie, 1, 10, and 100 nmol/L) elic-
ited rapid changes in impedance with CHO-hGPR32
-arrestin cells (Figure 3A). The anti-inflammatory hALX/
FPR2 agonist compound 4335 also evoked dose-depen-
dent changes in impedance with hGPR32-ovexpressing
cells similar to those elicited by RvD1 (Figure 3B).
Equimolar concentrations of RvD1-ME, 17(R/S)-methyl
RvD1-ME, and AT-RvD1 (Figure 3C) elicited similar
changes in impedance with CHO-hGPR32 -arrestin
cells. Again, DHA was less effective (Figure 3D).
RvD1 Controls PMN Infiltration and Specific
miRNAs in Genetically Engineered Mice
To assess in vivo and pinpoint RvD1 receptor-dependent
actions, we tested RvD1-ME in zymosan-induced perito-
A B
C D
Figure 2. RvD1, AT-RvD1, and their stable analogs directly act on hGPR32.
Ligand-receptor interactions were determined using the GPR32 -arrestin
system as in Figure 1. Dose-response activation curves are shown for RvD1
and DHA (A), RvD1-ME (B), 17(R/S)-methyl RvD1-ME (C), and AT-RvD1 (D).
Results are expressed as mean  SEM (n  4 to 6). RLU, relative lumines-
cence units.
Table 1. EC50 Values and Maximal Activity for RvD1 and Related
Receptor System
Compound EC50, mean (95% C
hALX/FPR2
RvD1 4.5  1011 (4.7  1012
RvD1-ME 3.7  1012 (3.3  1013
17(R/S)-methyl RvD1 5.4  1012 (1.2  1012
AT-RvD1 1.8  1010 (9.9  1012
DHA 1.9  109 (8.3  1010
hGPR32
RvD1 3.6  1012 (1.6  1012
RvD1-ME 4.6  1012 (1.0  1012
17(R/S)-methyl RvD1 2.5  1012 (7.8  1013
AT-RvD1 8.8  1012 (1.5  1012
DHA 2.2  1010 (2.0  1012
Ligand-receptor interactions were monitored using HEK-hALX/FPR2 or
of maximal activity was calculated relative to the maximal RLU values of RvD1.
CI, confidence interval; RLU, relative luminescence units.nitis with transgenic mice overexpressing hALX/FPR2.
hALX/FPR2 transgene was placed under the control of a
human CD11b promoter that drives high levels of trans-
gene expression in mature murine myeloid cells.32 As
shown in Figure 4, RvD1 (10 ng per mouse, i.v.) signifi-
cantly reduced (38%) the total peritoneal leukocyte
count at 24 hours in nontransgenic littermates (mean 
SD: 14.0  1.5  106 versus 22.6  3.0  106 in zymo-
san-treated mice; P  0.05, one-way analysis of vari-
ance). In hALX/FPR2 transgenic mice, RvD1 administra-
tion resulted in a further decrease (53%) in mean  SD
total leukocyte numbers from 15.6  3.2  106 in zymo-
san alone to 7.3  2.1  106 (P  0.05, one-way analysis
of variance) (Figure 4). RvD1 reduced PMN numbers in
hALX/FPR2 transgenic mice and nontransgenic litter-
mates by 30% and 40%, respectively (Figure 4). With
overexpression of hALX/FPR2, PMN numbers were
50% lower than in nontransgenic littermates at 10 ng of
RvD1 per mouse. In the absence of zymosan and RvD1,
resident peritoneal cell numbers were not significantly
different in ALX/FPR2 transgenic mice and their nontrans-
genic littermates (Figure 4).
RvD1 regulates miRNAs and their target genes asso-
ciated with resolution of acute inflammation.28 Since
RvD1 activates hALX/FPR2, we next tested whether RvD1
can regulate some of these miRNAs during self-limited
acute peritonitis in hALX/FPR2 transgenic mice. Small
RNA fractions were isolated from peritoneal lavages col-
lected 24 hours after injection of zymosan. RvD1 signifi-
cantly up-regulated miR-208a by 1.7-fold (P 0.01) (Fig-
ure 5A) and miR-219 by 1.8-fold (P  0.01) (Figure 5B)
compared with zymosan alone in hALX/FPR2 transgenic
mice. RvD1 significantly down-regulated miR-208a levels
by 0.4 fold (P  0.05) in wild-type (WT) mice (Figure 5A)
at 24 hours peritonitis, whereas it did not regulate miR-21,
miR-146b, and miR-302d levels (Figure 5C). These re-
sults indicate that RvD1 regulates specific miRNAs en-
dogenously expressed in resident peritoneal cells (Figure
5D), ie, miR-219 and miR-208a, in hALX/FPR2 transgenic
mice, which also confirms those miRNA identified28 as
proresolving in vivo.
To further investigate ALX/FPR2-dependent actions of
RvD1 in vivo, we next tested whether RvD1 could control
ures with Recombinant hALX/FPR2 and hGPR32 in a -Arrestin
l/L) RLUmax (10
4) % of max
 1010) 2.0 100
 1011) 2.4 125
 1011) 2.3 104
 109) 2.1 115
109) 1.0 50
 1012) 1.1 100
 1011) 1.3 116
 1012) 1.3 98
 1011) 1.0 124
 1012) 0.1 10
GPR32, a -arrestin cell system (see Materials and Methods). PercentageStruct
I) (mo
to 4.4
to 4.0
to 2.5
to 3.1
to 4.2 
to 8.2
to 2.1
to 8.1
to 5.0
to 2.5
CHO-h
Results are expressed as mean (95% CI, n  4 to 6).
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ALX/FPR2 receptor knockout mice, where LXA4 did not
regulate leukocyte trafficking.33 As shown in Figure 6, A
and B, RvD1 (10 ng per mouse, i.v.) significantly reduced
zymosan-initiated leukocyte (by 30%) and PMN (by
27%) infiltration 24 hours after zymosan injection in WT
mice. In ALX/FPR2/ mice, RvD1 did not regulate PMN
infiltration (Figure 6). This finding is consistent with recent
results with RvD1 in ALX/FPR2/ mice and leukocyte
trafficking.36 With zymosan alone, total leukocyte and
PMN values were not significantly different between ALX/
FPR2/ and WT mice. We also investigated the regula-
tion of miR-219 and miR-208a by RvD1 in ALX/FPR2/
mice. As shown in Figure 6, C and D, in receptor-deficient
mice, RvD1 did not significantly alter miR-208a or miR-
Figure 4. RvD1 reduction in PMN infiltration is enhanced in hALX/FPR2-ove
were injected with zymosan (1 mg per mouse i.p.), with or without RvD1-ME
exudate leukocytes were determined (see Materials and Methods): total leu
of total leukocytes and resident macrophages in control mice. Results are expressed
RvD1; †P  0.05, zymosan, WT versus ALX/FPR2-Tg; ‡P  0.01, zymosan  RvD1 W219 expression at 24 hours. In addition, RvD1 signifi-
cantly enhanced IL-10 levels in WT mice that was lost in
ALX/FPR2/ mice (Figure 7A). Taken together, these
results indicate that RvD1 regulation of leukocyte traffick-
ing, miR-208a, and IL-10 in mice depends on the endog-
enous ALX/FPR2 receptor.
Overexpression of miR-208a Up-Regulates
IL-10 Secretion in Human Macrophages
miR-208a down-regulates mRNA levels of the proinflamma-
tory PDCD4, a suppressor of IL-10 production37 in human
macrophages. Since RvD1 significantly up-regulated miR-
208a in humanmacrophages overexpressing hALX/FPR228
Figure 3. RvD1, Rv analogs, and compound 43
produce hGPR32-dependent changes in imped-
ance. Ligand-receptor–dependent changes in
impedance were continuously recorded with
real-time monitoring across cell monolayers us-
ing an ECIS system with hGPR32-expressing
-arrestin cells. Results are tracings obtained
from incubations with CHO-GPR32 -arrestin
cells plus RvD1 (1, 10, and 100 nmol/L) (A);
compound 43 (1, 10, and 100 nmol/L) (B); 100
nmol/L RvD1, RvD1-ME, and 17(R/S)-methyl
RvD1-ME (C); and 100 nmol/L RvD1 directly
compared with native DHA (D). Each tracing is
representative of n  3. Insets in A and B show
dose-dependent changes in cell impedance deter-
mined at 5 minutes of incubation of GPR32-over-
expressing cells with RvD1 or compound 43 or
vehicle alone. Results are expressed as mean 
SEM (n  3).
sing transgenic (Tg) mice peritonitis. hALX/FPR2-Tg mice and WT littermates
g per mouse i.v. Inflammatory exudates were collected at 24 hours and total
(left panel) and PMNs (middle panel). The right panel shows numbersrexpres
at 10 n
kocytesas mean  SEM (n  3 mice). *P  0.05, WT, zymosan versus zymosan 
T versus ALX/FPR2-Tg.
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AJP May 2012, Vol. 180, No. 5and in hALX/FPR2 transgenic mice (vide supra), we sought
to determine whether miR-208a directly regulates the anti-
inflammatory cytokine IL-10. As shown in Figure 7B, over-
expression of miR-208a in human macrophages resulted in
a significant increase in released IL-10 levels compared
with mock transfected macrophages.Discussion
In the present study, we determined the ligand selectivity
of the novel proresolving chemical mediator RvD1 and
related structures with two recently identified GPCRs,
hGPR32 and hALX/FPR2, that are activated by RvD1.
Figure 5. RvD1 stimulates specific proresolving
miRNAs in hALX/FPR2 transgenic (Tg) mice.
miRNA fractions were isolated from peritonitis
exudate samples of WT littermates and ALX/
FPR2-Tg mice challenged with zymosan (1 mg
per mouse) compared with mice given RvD1 (10
ng per mouse with zymosan). Real-time PCR
analyses of indicated miRNAs were performed
and results were analyzed by the 2CT method.
Fold change in expression levels in RvD1-treated
mice compared with zymosan alone were calcu-
lated from 2CT values. Results are expressed
as mean  SEM (n  3 in each group) fold
change in levels of miR-208a (A), miR-219 (B),
and miR-21, miR-146b, and miR-302d (C). *P 
0.05 for RvD1-treated versus zymosan-treated
WT or Tg mice; †P  0.05 for zymosan  RvD1–
treated Tg mice versus zymosan RvD1–treated
WT mice. D: miR-208a and miR-219 expression
levels determined by real-time PCR in peritoneal
cells from untreated mice.
Figure 6. Regulation of acute inflammation and
miRNA by RvD1 in ALX/FPR2 knockout mice.
Number of total leukocytes (A) and PMNs (B) in
peritoneal lavage fluid from WT or ALX/
FPR2/ mice injected with zymosan (1 mg per
mouse, i.p.) with or without RvD1-ME (10 ng per
mouse, i.v.). Lavage fluid samples were col-
lected 24 hours after initiation of peritonitis, and
cells were stained with anti-Ly-6G and F4/80
antibodies. Results are expressed as mean 
SEM (n  6 mice per group). *P  0.05 versus
zymosan-treated group. Expression of miR-208a
(C) and miR-219 (D) in exudate cells from WT or
ALX/FPR2/ mice 24 hours after injection of
zymosan plus RvD1-ME (10 ng per mouse, i.v.)
or zymosan plus saline. Relative expression of
miRNAs was determined using real-time PCR.
Results are expressed as mean  SEM of fold
changes in expression (n  6 mice per group).
***P  0.001 versus zymosan-treated group.
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hALX/FPR2 interactions regulate acute inflammatory re-
sponses in vivo and selected miRNA expression in hALX/
FPR2 transgenic mice to reduce inflammation. Along
these lines, an RvD1-regulated miR-208a identified in
hALX/FPR2 transgenic mice also controlled release of the
anti-inflammatory cytokine IL-10 in human macrophages.
We examined RvD1, AT-RvD1, and their analogs in
hALX/FPR2 and hGPR32 receptor–overexpressing cells
using -arrestin reporter systems to access ligand poten-
cies since each is known to display potent actions in vivo
in a range of animal models (vide supra).3 In these exper-
iments, the RvD1 precursor DHA proved to be less active
with these receptors (Figures 1–3). Ligand-receptor–
stimulated changes were also monitored with electrode-
based impedance measurements, which reflect changes
in the actin cytoskeletal framework.38 Because RvD1 reg-
ulates actin cytoskeletal changes,27 we sought to use this
system where these changes reflect GPCR activation. As
shown in Figure 3, A and B, RvD1 and the anti-inflamma-
tory compound 4335 each elicited dose-dependent
changes in impedance in hGPR32-overexpressing CHO
cells. Similarly, RvD1, AT-RvD1, and their analogs
evoked rapid changes in impedance at equimolar con-
centrations (Figure 3, C and D) with these cells, indicat-
ing that activation of this receptor is consistent with the
bioactivity of RvD1 and related structures. These results
also indicate that in the 17S-containing RvD1 and the
17R- as in the aspirin-triggered epimer AT-RvD1, each
configuration at carbon position C17, ie, C17 alcohol
groups, is efficiently recognized by receptors hGPR32
and hALX/FPR2. RvD1 showed a lower EC50 for the
hALX/FPR2 receptor in the -arrestin system, suggesting
that in these conditions, the S configuration of the C17
hydroxyl group is preferred for interactions with hALX/
FPR2 receptor. Also, the addition of a carboxyl methyl
Figure 7. Regulation of IL-10 levels by RvD1 in peritonitis and by miR-208a
in human macrophages. A: IL-10 levels were determined in mALX/FPR2/
mice (n  3 to 6). *P  0.05 versus mice receiving zymosan alone. B: IL-10
levels were determined in human macrophages transiently overexpressing
miR-208a or control vector (n  3). *P  0.05 versus control vector–trans-
fected macrophages.ester group to RvD1 (denoted RvD1-ME) retained its abil-ity to activate with these receptors. In contrast, the native
DHA structure that lacks functional alcohol groups was
far less effective than was RvD1 at activating these re-
ceptors within the active concentration/dose range of
RvD1 and closely related structures. Although DHA at
109 mol/L can partially activate ALX/FPR2, this seems to
be relatively weak compared with RvD1 (Table 1). RvD1
and its stable analogs were 2 log orders of magnitude
more potent (EC5010
12 to 1011 mol/L). In this regard,
RvD1 is present in human plasma at5 1011 mol/L,39
consistent with its agonist actions.
Earlier, we demonstrated, using a single cell–monitor-
ing microfluidic chamber, the specific PMN actions of
RvD1 at nanomolar levels and its direct actions with hu-
man PMN that clearly require conversion of DHA, the
precursor of RvD1, to stimulate actions on human PMN.16
Thus, the present results also confirm that specific ac-
tions of RvD1 and its analogs are mediated via interac-
tions with surface receptors. Because RvD1 interacts with
hALX/FPR2,27 we also tested whether RvD1 can dampen
inflammation in hALX/FPR2 transgenic mice. As shown in
Figure 4, RvD1 as low as 10 ng i.v. decreased total
leukocyte infiltration in zymosan-induced murine perito-
nitis in WT mice. In parallel, 10 ng of RvD1 significantly
reduced total leukocyte and PMN numbers in hALX/FPR2
mice compared with zymosan alone. These results indi-
cate that RvD1 signals via ALX/FPR2 in vivo for its anti-
inflammatory actions. Of interest, RvD1 did not change
the expression of ALX/FPR2 in peritoneal exudate cells
from WT mice, which was determined by quantitative
real-time PCR analyses (see Supplemental Figure S1 at
http://ajp.amjpathol.org). hALX/FPR2 was initially identi-
fied as the receptor for LXA4
4 and was later shown to be
activated by aspirin-triggered lipoxin (15-epimer of
LXA4),
40 the glucocorticoid-derived annexin peptide,41
and RvD127 and by many proinflammatory peptides (see
reviews1,42). Each of these proresolving mediators inter-
acting with hALX/FPR2 signals for anti-inflammatory and
proresolving actions. By comparison, as low as 10 ng of
aspirin-triggered lipoxin per mouse blocked zymosan-
stimulated PMN infiltration by 50% in hALX/FPR2 trans-
genic mice compared with in WT littermates.32
In the present study, we also assessed the anti-inflam-
matory actions of an ALX/FPR2 agonist, compound 43
(see Supplemental Figure S2 at http://ajp.amjpathol.org),
that was identified by a medical chemical screening ap-
proach.35 In Supplemental Figure S2 (available at http://
ajp.amjpathol.org), this receptor agonist, compound C43,
blocked total leukocyte and PMN infiltration in vivo in
murine zymosan peritonitis, confirming its anti-inflamma-
tory actions. Recently, it was reported that targeted
knockdown of the murine ALX/FPR2 receptor diminished
the anti-PMN activities of its ligands, namely, LXA4, an-
nexin peptide, and compound 43, and gave an exacer-
bated inflammatory phenotype in mice.33 In these ALX/
FPR2-null mice, RvD1’s protective action (ie, reducing
peritoneal PMN infiltration at 4 hours with 1 and 10 ng per
mouse) was also diminished, indicating the crucial role of
ALX/FPR2 expression in RvD1 biology in the mouse.36
Along these lines, low-dose aspirin in humans is protec-
tive and anti-inflammatory in a cantharidin-induced acute
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pended on the endogenous biosynthesis of 15-epimer of
LXA4 in skin blisters and on the up-regulation of hALX/
FPR2 expression in peripheral blood leukocytes.43 Also,
the amplitude and time course of 15-epimer of LXA4 and
hALX/FPR2 appearance were key determinants in the
severity of inflammation and the onset of resolution in
these individuals,10 thus unveiling in humans the impor-
tant role of hALX/FPR2 and its agonists in governing host
responses. Recently, it was shown that ALX/FPR2 ex-
pression is up-regulated during the menstrual phase of
the cycle and in decidua tissue from the first trimester of
pregnancy. LXA4 reduces the inflammatory cytokines in
human endometrium and decidua tissue, indicating that
the LXA4-ALX/FPR2 axis regulates inflammatory re-
sponses in human endometrium and decidua of early
pregnancy.44 Hence, it would not be surprising if the
ligand-receptor interactions documented in the present
study can also be of interest in other organ systems in
addition to the immune response and its endogenous
resolution mechanisms.
In the effector immune system, certain GPCRs can be
activated by bias ligands that couple different cellular
responses, as in the case of ALX/FPR2, which interacts
with peptides and lipid mediators that function as proin-
flammatory or anti-inflammatory and proresolving.8,42
This also seems relevant for the resolvin E1 receptor
ChemR23, which binds both peptides and is stereose-
lective for RvE1 and its proresolving actions.45 In view of
these findings, it is possible that proresolving ligands use
receptors that play a role in initiation and in resolution and
termination of the inflammatory response to evoke novel
tissue signals required for resolution and homeostasis.
RvD1 acts via specific miRNAs that control the inflamma-
tory response, defining the first RvD1-GPCR miRNA sig-
nature of resolution in inflammatory exudates.28 To further
address these novel proresolving mechanisms in the
present experiments, we also assessed regulation of
these key miRNAs by RvD1 in vivo using transgenic mice
that overexpress the human receptor for LXA4, hALX/
FPR2. Among the analyzed miRNAs, RvD1 given at 10 ng
per mouse i.v. selectively up-regulated miR-208a and
miR-219 in hALX/FPR2 transgenic mice at 24 hours of
peritonitis compared with those challenged with zymosan
alone or with their nontransgenic littermates. In compar-
ison, RvD1 did not up-regulate either miR-208a or one of
its target gene products, IL-10, in genetically modified
ALX/FPR2 knockout mice. This finding in receptor-defi-
cient mice further corroborates the evidence that in vivo
actions of RvD1 are mediated, at least in part, by the
ALX/FPR2 receptor, which, in turn, regulates proresolving
miRNAs and target genes. In human macrophages, miR-
208a and miR-219 were identified as RvD1-GPCR–regu-
lated miRNAs along with miR-146b and miR-21. These
miRNAs were also regulated by RvD1 in murine perito-
neal exudate leukocytes. These miRNAs and their target
genes seem to belong to an integral network of regulatory
molecules that promote resolution of acute inflamma-
tion.28 In the present experiments, miR-208a is down-
regulated by RvD1 in WT littermates and is up-regulated
in hALX/FPR2-overexpressing receptor transgenic mice.These findings indicate the existence of a specific RvD1
receptor-dependent circuit that is required for the regu-
lation of miR-208a. These results also suggest that hu-
man and mouse ALX/FPR2 regulate miR-208a in vivo dif-
ferently.
Recently, we found that RvD1 up-regulates miR-208a
and reduces miR-219 expression in human macro-
phages overexpressing hGPR32, which was not the case
for human ALX. RvD1 with human ALX overexpression
did not increase miR-208a in human macrophages,28
whereas overexpression of hALX/FPR in transgenic mice
(Figure 5A) gave an increase in miR-208a when RvD1
was administered. Hence, the direct actions of RvD1 with
isolated human macrophage overexpression of ALX28
versus in vivo administration of RvD1, as in the present
results (Figure 5A), give different levels of miR-208a. This
difference with miR-208a might reflect the in vivo inflam-
matory exudate environment or possibly species differ-
ences with RvD1 postreceptor signal transduction. Also,
it is possible that miR-208a regulation in vivo in mice
could reflect its regulation via macrophages and other
inflammatory exudate cells.
As for their target genes, miR-219 targets 5-lipoxygen-
ase and regulates leukotriene B4 production.
28 miR-208a
overexpression in human macrophages increased IL-10
(Figure 7). miR-208a specifically targets and down-regu-
lates PDCD4, a proinflammatory regulatory protein that
reduces IL-10 and promotes activation of the NF-B path-
way.28,37 The present experiments with RvD1 are consis-
tent with this and demonstrate that miR-208a overexpres-
sion in human macrophages up-regulates IL-10. This is
likely important because IL-10 is a pivotal cytokine in
inflammation and its resolution. Hence, IL-10 regulation
by a local mediator, namely, RvD1, that is biosynthesized
from an essential dietary -3 fatty acid may have wide-
ranging implications in human health and in diseases
such as cardiovascular disease (recently reviewed by De
Caterina46). Unlike human macrophages, the down-reg-
ulation of miR-208a by RvD1 was not associated with
concurrent increases in PDCD4 levels in mice.28 This
finding suggests that PDCD4 might not be a direct target
of miR-208a in murine peritoneal exudate cells. Indeed, it
is also known that expression patterns and functions of
miRNAs are not strictly conserved between species.47,48
This may also explain, in part, the increases in IL-10
levels in WT mice in response to RvD1 (Figure 7), albeit
decreases in miR-208a levels in mice. Along these lines,
IL-10 is expressed in several cell types and, hence, may
have cell-specific transcriptional and posttranscriptional
regulatory mechanisms.49 Since RvD1 up-regulated
IL-10 levels in peritoneal exudate cells, it is possible that
RvD1 may use additional mechanisms in these cells that
are independent of miR-208a to regulate IL-10 produc-
tion and secretion.
Along these lines, the original complete structural elu-
cidation of the first bioactive coined RvE1 relied on its
ability to reduce PMN infiltration and proinflammatory me-
diators and to evoke the nonphlogistic activation of
monocytes/macrophages.45,50 In more aggressive dis-
ease models associated with inflammation, infection, and
tissue destruction, such as TNBS-induced mouse coli-
2026 Krishnamoorthy et al
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chronic inflammation, as in rabbit periodontal disease,52
low doses of RvE1 proved tissue protective and in certain
settings stimulated regeneration of the local tissues in-
jured during PMN-mediated inflammatory responses. In
support of this proresolving mechanism being tissue pro-
tective, RvD2 and AT-RvD1 were recently demonstrated
by Bento et al25 to be potent protective mediators in
TNBS and DDS colitis in murine systems with AT-RvD1
relying on ALX/FPR2 for their protective actions in murine
tissues. Hence, by activating different proresolving re-
ceptors and tissue circuits, specific proresolving media-
tors, such as LXA4, RvE1, and RvD1 as ligands, each
biosynthesized locally from different substrates, regulate
leukocyte functional responses and stimulate tissue res-
olution.
In summation, the potent proresolving mediator RvD1,
its aspirin-triggered epimer AT-RvD1, and the synthetic
analogs RvD1-ME and 17(R/S)-methyl RvD1 each selec-
tively activates recombinant hALX/FPR2 and hGPR32 re-
ceptors. RvD1 dampens acute inflammation in vivo in part
via the hALX/FPR2 receptor, as demonstrated in trans-
genic mice in situ. In peritoneal exudate leukocytes from
these mice, RvD1 up-regulates miR-208a, which targets
PDCD4, a proinflammatory signaling molecule that gives
up-regulation of IL-10 in human macrophages. Together,
the findings of the present study establish the ligand
selectivity for proresolving agonists of hALX/FPR2 and
hGPR32 and indicate that RvD1 via its interactions with
these specific GPCRs regulates miRNAs that target spe-
cific resolvers. They also shed light on new GPCR-de-
pendent mechanisms for RvD1 and related structures
and their actions in controlling the magnitude of the in-
flammatory response and stimulating its resolution.
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